Company / Operating Cash Flow per Share
VYNE Therapeutics Inc. Operating Cash Flow per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$2.29
FY2025
5-year range
-$18.94 / -$1.80
FY2021-FY2025
Trend
-27.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow per Share has fluctuated over the past 8 years, ranging from $-18.94 in FY2022 to $-0.43 in FY2018.
Based on SEC 10-K filings.
-2.29 in FY2025.
Improved from $-9.04 to $-2.29 over the past 2 years.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 27.5% year-over-year.
- Peak operating cash flow per share was recorded in FY2018.
- Lowest operating cash flow per share in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.29 | -27.5% |
| FY2024 | -$1.80 | +80.1% |
| FY2023 | -$9.04 | +52.3% |
| FY2022 | -$18.94 | -496.9% |
| FY2021 | -$3.17 | +57.9% |
| FY2020 | -$7.53 | -519.8% |
| FY2019 | -$1.21 | -184.2% |
| FY2018 | -$0.43 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026